Prevention and treatment of intertrigo in large skin folds of adults: a systematic review

Patriek Mistiaen, Meike van Halm-Walters, Patriek Mistiaen, Meike van Halm-Walters

Abstract

Background: Intertrigo in the large skin folds is a common problem. There is a plethora of treatments, but a lack of evidence about their efficacy. A nursing guideline on this matter had to be updated and broadened in scope to other health care professionals.

Methods: A systematic review was performed. Thirteen databases were sensitively searched, supplemented by reference tracking and forward citation searches. All types of empirical research relating to the prevention or treatment of intertrigo were included. Study selection, assessment of bias, data-extraction and analysis were done by two independent review-authors.

Results: Sixty-eight studies fulfilled the inclusion criteria. Only 4 studies were RCTs and even these had a considerable risk of bias. Study populations were generally small.No studies were found about the prevention of intertrigo. The therapies concerned mostly the topical application of antimycotics, corticosteroids, antibiotics, antiseptics or a combination of these. Besides these pharmaceutical interventions, surgical breast reduction was also studied. Although most study-authors were positive, we could not draw firm conclusions about any of the pharmaceutical interventions. Even patients that received placebo intervention showed improvement. There is weak evidence that reduction mammaplasty may be helpful to treat inframammary intertrigo. All research found had considerable risk of bias, prohibiting firm conclusions.

Conclusions: There is no evidence at all about the prevention of intertrigo and there is no firm evidence about its treatment. Well designed studies are needed.

Figures

Figure 1
Figure 1
Flow chart inclusion process.

References

    1. van Duijn HJ. In: Minor ailments in primary care - An evidence based approach. Eekhof J, Knuistingh Neven A, Verheij T, editor. Maarssen: Elsevier Gezondheidszorg; 2005. Intertrigo; pp. 63–65.
    1. van Duijn HJ, Mulder J. Kleine kwalen in de huisartsgeneeskunde: smetten onder de borsten. Ned Tijdschr Geneeskd JID - 0400770. 1988;132:1842–1843.
    1. Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician. 2005;72:833–838.
    1. Arndt K, Bowers K. Manual of dermatologic therapeutics. 6. Philadelphia: Lippincott Williams & Wilkins; 2002.
    1. Itin P. [Intertrigo--a therapeutic problem circle] Ther Umsch. 1989;46:98–101.
    1. Halfens RJ, Meijers J, Neyens JCL, Offermans MPW. Rapportage resultaten Landelijke Prevalentiemeting Zorgproblemen. Maastricht: Maastricht University; 2008.
    1. Halfens R, Wansink S. Landelijke prevalentiemeting decubitus en andere zorgproblemen: resultaten zevende jaarlijkse meting 2004. Maastricht: Universiteit Maastricht; 2004.
    1. Halfens R, Janssen M, Meijers J. Landelijke prevalentiemeting zorgproblemen: rapportage resultaten 2006. Maastricht: Universiteit Maastricht; 2006.
    1. Mistiaen P, Wagner C, Bours G, Halfens R. Prevalentiemeting van smetten in Nederlandse intramurale zorginstellingen. Utrecht: NIVEL; 2003.
    1. Mistiaen P, Poortvliet M. In: Landelijke prevalentiemeting zorgproblemen: Rapportage resultaten 2005. Halfens R, Janssen M, Meijers J, Mistiaen P, editor. Maastricht: Universiteit Maastricht; 2005. Smetten; pp. 77–86.
    1. Halfens R, Meijers J, Neyens J, Offermans M. Landelijke prevalentiemeting zorgproblemen: rapportage resultaten 2007. Maastricht: Universiteit Maastricht; 2007.
    1. McMahon R. The prevalence of skin problems beneath the breasts of in-patients. Nurs Times. 1991;87:48–51.
    1. LEVV; NVDVV; NIVEL. Smetten (intertrigo): preventie en behandeling. landelijke richtlijn verpleging en verzorging. Utrecht: LEVV; 2004.
    1. Mistiaen P, Poot E, Hickox S, Jochems C, Wagner C. Preventing and treating intertrigo in the large skin folds of adults: a literature overview. Dermatol Nurs. 2004;16:43–57.
    1. National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2009.
    1. Chapman M, Brown J. Tacrolimus 0.1% ointment for intertrigo. J Am Acad Dermatol. 2005;52:61. doi: 10.1016/j.jaad.2004.04.039.
    1. Chapman MS, Brown JM, Linowski GJ. 0.1% tacrolimus ointment for the treatment of intertrigo. Arch Dermatol. 2005;141:787. doi: 10.1001/archderm.141.6.787-a.
    1. Spector JA, Singh SP, Karp NS. Outcomes after breast reduction - Does size really matter? Annals of Plastic Surgery. 2008;60:505–509. doi: 10.1097/SAP.0b013e31816f76b5.
    1. Spector JA, Karp NS. Reduction mammaplasty: A improvement at any size. Plastic and Reconstructive Surgery. 2007;120:845–850. doi: 10.1097/01.prs.0000277660.49802.76.
    1. Cullen SI, Rex IH, Thorne EG. A comparison of a new antifungal agent, 1 percent econazole nitrate (Spectazole(registered trademark)) cream versus 1 percent clotrimazole cream in the treatment of intertriginous candidosis. Curr Ther Res Clin Exp. 1984;35:606–609.
    1. Hedley K, Tooley P, Williams H. Problems with clinical trials in general practice--a double-blind comparison of cream containing miconazole and hydrocortisone with hydrocortisone alone in the treatment of intertrigo. Br J Clin Pract. 1990;44:131–135.
    1. Miura Y, Onuki M, Takahashi S, Seiji M, Akihiko SATO, Kagawa S. A Double-Blind Study on Utility of Econazole Cream in Dermatomycosis. Rinsho Hyoka (Clinical Evaluation) 1979;7:83–108.
    1. Nozickova M, Koudelkova V, Kulikova Z, Malina L, Urbanowski S, Silny W. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol. 1998;37:703–705. doi: 10.1046/j.1365-4362.1998.00541.x.
    1. National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2009.
    1. Bergson VS, Franklin WH. Temetex in the treatment of steroid-responsive dermatoses. J Int Med Res. 1977;5:33–36.
    1. Schindera I. Current intertrigo therapy - Treatment results with Hamamelis virginiana. Forsch Komplementarmed Klass Naturheilkd. 1999;6:31–32. doi: 10.1159/000057145.
    1. Grigoriu A, Grigoriu D. Superficial mycoses: Ketoconazole treatment. Mykosen. 1982;25:258–262.
    1. Puiatti P, Cervetti O, Forte M, Zina G. Ketoconazole treatment in superficial mycoses. Drugs Exp Clin Res. 1986;12:405–407.
    1. Almeyda JJ, Feiwel M, Thorne N, Vickers CF. "Timodine" cream in the treatment of flexural dermatoses and napkin rash. Practitioner. 1974;213:864–867.
    1. Alteras I, Cojocaru I. [Antifungal activity of pimaricin] Mycoses. 1969;12:139–149. doi: 10.1111/j.1439-0507.1969.tb03442.x.
    1. Amerighi F, Spagnoli U. Experiments in treatment using ketoconazole in new 2% dermatological powder. G Ital Dermatol Venereol. 1984;119:XIII–XXVI.
    1. Anonymous. Estudo da associaçäo de fluprednilideno, sulfato de gentamins e 5-cloro-8-hidroxiquinolina no tratamento de lesoes infectadas/Association of flupredniliden, gentamicin sulphate and 5-chloro-8-hydroxiquinolin in the treatment of infectal lesions. Folha Med. 1989;99:45–48.
    1. Aussems J. [Clinical study of a bufexamac-nystatin-neomycin combination in dermatology] Brux Med. 1972;52:797–799.
    1. Baran R, Beurey J, Civatte J. Multicentric clinical trial of a new combination of a broad spectrum antimycotic in a dermocorticoid. Sem Hop. 1979;55:269–272.
    1. Durand JR. Clinical trial of a mixture of neomycin, bacitracin, natamycin and dexamethasone. MEDITERR MED. 1975;3:71–74.
    1. Engel MF. Amphotericin B lotion in monilial intertrigo: a double-blind paired comparison study. Arch Dermatol. 1965;92:687. doi: 10.1001/archderm.1965.01600180079014.
    1. Franks AG, Taschdjian CL, Thorpe GA. Effect of candicidin in intertriginous and paronychial moniliasis. J Invest Dermatol. 1954;23:75–76.
    1. Gip L. [Clinical testing of Fungiplex ointment on a geriatric material with intertriginous Candida mycosis] Dermatol Wochenschr. 1966;152:482–484.
    1. Gisslen H, Hersle K, Mobacken H. Topical treatment of cutaneous candidiasis with 5 fluorocytosine compared with nystatin. Dermatologica. 1974;148:362–365. doi: 10.1159/000251929.
    1. Grupper C. [Treatment of some dermatoses caused by yeast fungi (moniliasis of the pyodermitis vegetans type, intertrigo, onyxis and perionyxis) with the new fungicide: mycostatin or nystatin.] Bull Soc Fr Dermatol Syphiligr. 1954;61:495–498.
    1. Guha DK, Behera FC, Patro SC. Topical therapy with Jadit (Buclosamide) in dermatomycoses. INDIAN J DERMATOL. 1974;19:61–63.
    1. Guilhou E. Miconazole plus hydrocortisone in dermatology. MEDITERR MED. 1979;7:22–23.
    1. Hempel M. [Clinical experiences in the local treatment of dermatomycoses with Econazole lotion] Mykosen. 1975;18:213–219.
    1. Masse R, Nedelec J, Dorval JC. Therapeutic trial of an econazole-triamcinolone combination. OUEST MED. 1980;33:157–159.
    1. Otcenasek M, Pec J, Moravcik P. [Naftifin--laboratory and clinical experience with a new antimycotic from the allylamine group] Cas Lek Cesk. 1993;132:406–409.
    1. Radovic-Kovacevic V, Ratkovic R, Milenkovic A. [Obytin in the treatment of superficial skin mycoses] Med Pregl. 1990;43:329–331.
    1. Reiffers J. [Clinical report of triclosan, a new topical with antifungicidal and antimicrobial activity (CGP 433--Logamel) (author's transl)] Schweiz Rundsch Med Prax. 1981;70:1050–1053.
    1. Rosanove R. "Kenacomb" cream in the treatment of intertrigo. Med J Aust. 1967;2:676–678.
    1. Scherwitz C. [Clinical testing of Econazole skin lotion and cream in dermatomycoses] Z Hautkr. 1977;52:117–125.
    1. Schmidt P. Therapeutic experience with CG 3225 polyvalent ointment (Topsym) CLIN TRIALS J. 1975;12:53–59.
    1. Schwarz KJ, Much T, Konzelmann M. [Evaluation of econazol in 594 cases of skin mycosis (author's transl)] Dtsch Med Wochenschr. 1975;100:1497–1500. doi: 10.1055/s-0028-1106606.
    1. Siboulet A. [Econazole spray-powder in dermo-venereology (authors transl)] Schweiz Rundsch Med Prax. 1976;65:977–981.
    1. Somorin AO. Clinical evaluation of tioconazole in dermatophyte infections. Curr Ther Res Clin Exp. 1985;37:1058–1061.
    1. Szepes E, Schneider I. Ciclopiroxolamine in the treatment of dermatomycoses. Mykosen. 1986;29:382–386.
    1. Taube KM, Duhr M, Koepke M, Haustein UF. Treatment of fungal infections of the skin with tioconazole. Z DERMATOL. 1995;181:125–128.
    1. Thomas J, Saint-Andre P, Cornudet B. [Local use of thiabendazole in the treatment of certain superficial mycoses] Bull Soc Pathol Exot Filiales. 1971;64:316–322.
    1. Varma R, Cantrell W, Werlinger K, Elewski BE. A new gel formulation of miconazole nitrate 2% for the treatment of chronic intertrigo. Cosmetic dermatology. 2007;20:43–44.
    1. Vogt G. Intertriginous mycosis and its treatment. ARZTL KOSMETOL. 1985;15:178–183.
    1. Wanic A. [Therapeutic trials of various skin diseases using chinoline and chinaldine derivatives] Z Haut Geschlechtskr. 1967;42:27–32.
    1. Wurster J. Treatment of intertriginous dermatosis and diaper dermatitis with a combination of econazole and zinc oxide. ARS MED. 1993;83:792–795.
    1. Becker SW. An eight investigator analysis of a newly formulated low dosage corticosteroid. Cutis. 1973;12:283–285.
    1. Gatti JC, Cardama JE, Balina LM. [Our observations with the topical use of Fluocinolone acetonide] Dia Med. 1963;35:1509.
    1. Hofer P. Treatment of skin diseases with an antiinfective and antiinflammatory gel (Exosterol) containing phenylmercuric borate and dexamethasone pivalate. Praxis. 1974;63:1550–1553.
    1. Marton K, Traore N. Clinical observations on the use of ftorocort ointment in tropical areas. THER HUNG. 1977;25:29–31.
    1. Vallette P, Bonerandi, Sayag J. [Stapolidex in dermatology] Bull Soc Fr Dermatol Syphiligr. 1968;75:490–494.
    1. Venier A, Carnevali P, Alessandrini A, Urbani S. Controlled clinical trial of a topical formulation of fluocortolone (as privalate and caproate esters) plus chlorquinaldol. CLIN EUR. 1982;21:932–939.
    1. Bonnefoy M, Doss N, Nouira R, Boge T. Comparative study of Cicalfate Lotion(registered trademark) versus eosine for large skin folds intertrigo treatment. Nouv Dermatol. 2008;27:257.
    1. McMahon R. An evaluation of topical nursing interventions in the treatment of submammary lesions. Journal of Wound Care. 1994;3:365–366.
    1. Atterhem H, Holmner S, Janson PE. Reduction mammaplasty: symptoms, complications, and late results. A retrospective study on 242 patients. Scand J Plast Reconstr Surg Hand Surg. 1998;32:281–286. doi: 10.1080/02844319850158615.
    1. Brown AP, Hill C, Khan K. Outcome of reduction mammaplasty--a patients' perspective. Br J Plast Surg. 2000;53:584–587. doi: 10.1054/bjps.2000.3380.
    1. Davis GM, Ringler SL, Short K, Sherrick D, Bengtson BP. Reduction mammaplasty: long-term efficacy, morbidity, and patient satisfaction. Plast Reconstr Surg. 1995;96:1106–1110. doi: 10.1097/00006534-199510000-00015.
    1. Glatt BS, Sarwer DB, O'Hara DE, Hamori C, Bucky LP, LaRossa D. A retrospective study of changes in physical symptoms and body image after reduction mammaplasty. Plast Reconstr Surg. 1999;103:76–82. doi: 10.1097/00006534-199901000-00013.
    1. Gonzalez F, Walton RL, Shafer B, Matory J, Borah GL. Reduction mammaplasty improves symptoms of macromastia. Plast Reconstr Surg. 1993;91:1270–1276. doi: 10.1097/00006534-199306000-00013.
    1. Heddens CJ. Postoperative survey of reduction mammoplasty patients. Plast Surg Nurs. 1993;13:148–155.
    1. Kakagia D, Harkiolakis G, Sgouras N. Symptomatic macromastia: A quality of life evaluation after reduction mammaplasty. Breast J. 1998;4:152–155. doi: 10.1046/j.1524-4741.1998.430152.x.
    1. Makki AS, Ghanem AA. Long-term results and patient satisfaction with reduction mammaplasty. Ann Plast Surg. 1998;41:370–377. doi: 10.1097/00000637-199810000-00004.
    1. McMahan JD, Wolfe JA, Cromer BA, Ruberg RL. Lasting success in teenage reduction mammaplasty. Ann Plast Surg. 1995;35:227–231. doi: 10.1097/00000637-199509000-00001.
    1. Moskovitz MJ, Muskin E, Baxt SA. Outcome study in liposuction breast reduction. Plast Reconstr Surg. 2004;114:55–60. doi: 10.1097/01.PRS.0000127795.84891.A7.
    1. Rioja Torrejón LF, Pedreño Guerao F, Deza Rodríguez P, Benítez Gumá J, Redondo Camacho A, Haro Padilla JM. [Breast hipertrophy. Aesthetic deformity or it must be included in the national health service] Cirugía Plástica Ibero-Latinoamericana. 2006;32:99–106. doi: 10.4321/S0376-78922006000200004.
    1. Schnur PL, Schnur DP, Petty PM, Hanson TJ, Weaver AL. Reduction mammaplasty: an outcome study. Plast Reconstr Surg. 1997;100:875–883. doi: 10.1097/00006534-199709001-00008.
    1. Shakespeare V, Cole RP. Measuring patient-based outcomes in a plastic surgery service: breast reduction surgical patients. Br J Plast Surg. 1997;50:242–248. doi: 10.1016/S0007-1226(97)91154-1.
    1. Wagner DS, Alfonso DR. The influence of obesity and volume of resection on success in reduction mammaplasty: an outcomes study. Plast Reconstr Surg. 2005;115:1034–1038. doi: 10.1097/01.PRS.0000154213.06888.F9.
    1. Alexander JO. Polynoxylin (Anaflex) in dermatology. Br J Dermatol. 1962;74:364–371.
    1. Belaiche P. Traitement des infections cutanees par l'huile essentielle de melaleuca alternifolia.cheel. Phytotherapy. 1985. pp. 15–17.
    1. Huyke C, Reuter J, Maunz H, Muller ML, Schempp M. Betulin-based ointment for the topical treatment of exudative skin conditions. Merkurstab. 2008;61:370–376.
    1. Profirov D, Nikiforov N. On the antimycotic effect of the Mericleri salt. Folia Med (Plovdiv ) 1974;16:143–145.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅